HC Wainwright Reiterates “Buy” Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $20.00 price target on the stock.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ CKPT traded up $0.07 during midday trading on Monday, reaching $2.37. 264,999 shares of the stock were exchanged, compared to its average volume of 446,938. Checkpoint Therapeutics has a 12 month low of $1.30 and a 12 month high of $3.62. The company has a market capitalization of $106.70 million, a price-to-earnings ratio of -0.85 and a beta of 1.29. The business has a 50-day simple moving average of $2.32 and a two-hundred day simple moving average of $2.02.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its earnings results on Monday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.11. The business had revenue of $0.04 million during the quarter. Equities research analysts expect that Checkpoint Therapeutics will post -0.81 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO James F. Oliviero III sold 24,610 shares of the business’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total value of $50,450.50. Following the sale, the chief executive officer now directly owns 1,977,170 shares in the company, valued at $4,053,198.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CFO William Garrett Gray sold 13,038 shares of the firm’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total value of $26,858.28. Following the completion of the transaction, the chief financial officer now owns 672,186 shares of the company’s stock, valued at $1,384,703.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO James F. Oliviero III sold 24,610 shares of the business’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $2.05, for a total transaction of $50,450.50. Following the sale, the chief executive officer now directly owns 1,977,170 shares in the company, valued at $4,053,198.50. The disclosure for this sale can be found here. Company insiders own 2.10% of the company’s stock.

Institutional Trading of Checkpoint Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in shares of Checkpoint Therapeutics during the 2nd quarter worth about $34,000. Lindbrook Capital LLC bought a new stake in Checkpoint Therapeutics in the first quarter valued at approximately $62,000. 180 Wealth Advisors LLC acquired a new stake in shares of Checkpoint Therapeutics in the second quarter valued at approximately $96,000. Choreo LLC lifted its position in shares of Checkpoint Therapeutics by 200.9% in the first quarter. Choreo LLC now owns 57,922 shares of the company’s stock valued at $119,000 after buying an additional 38,672 shares during the last quarter. Finally, PVG Asset Management Corp bought a new position in shares of Checkpoint Therapeutics during the 2nd quarter worth approximately $295,000. Institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.